Proven in Relapsing MS. Proven in PPMS.

OCREVUS is the first and only FDA approved treatment for both relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).

OCREVUS for relapsing MS and PPMS

*REBIF® (Interferon beta-1a) is a registered trademark of EMD Serono, Inc.
Disability progression was measured using a tool called the Expanded Disability Status Scale (EDSS). Disability progression was confirmed 3 months after the initial neurological change.
Disability progression was also confirmed after 6 months.

Before receiving OCREVUS, tell your healthcare provider if you think you have an infection and if you have ever taken, are taking, or plan to take medicines that affect your immune system, such as chemotherapy, immunosuppressants, or other treatments for MS. Also tell your healthcare provider if you have had a recent vaccination or are scheduled to receive vaccinations.

  • Your first dose of OCREVUS will be given as 2 separate infusions, 2 weeks apart. These will last about 2.5 hours each
  • Every dose after your first will be given as 1 single infusion 6 months apart, lasting about 3.5 hours
  • Before each infusion of OCREVUS you will receive corticosteroids and an antihistamine to help reduce infusion-related reactions (IRRs)
  • OCREVUS should be given under the close supervision of an experienced healthcare provider with access to appropriate medical support to manage severe reactions such as serious IRRs
  • Everyone who receives OCREVUS will be asked to stay at the infusion center for at least an hour following treatment
  • This is so the healthcare team can be with you to make sure you’re doing well and aren’t experiencing side effects

The length of infusion could be longer if an IRR occurs.